Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Non-GAAP Research & Development Expense by Quarter
Non-GAAP Research & Development Expense ($M) ($M)
Amgen Non-GAAP Research & Development Expense: $1,851M in Q2 2026, up 9.9% from a year earlier.
Where the Q2 2026 figure comes from
“|| Non-GAAP research and development expenses | $ | 1,851 | $ | 1,685 | $ | 3,562 | $ | 3,160”
Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up non-GAAP Research & Development Expense
Cite this data
StockData. (2026). Amgen Non-GAAP Research & Development Expense ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng-rd
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.